Figure 2.

Proliferative effects of type I and type II IFNs on blood IgM⁺IgD⁺ B cells. The lymphoproliferative effects of rIFNa and rIFNγ were determined by incubating PBLs at 20°C with 50 ng/ml rIFNa, 20 ng/ml rIFNγ or media alone. For each condition, wells containing 10 μg/ml of unlabelled anti-IgM were also included. After 72 h, cells were labeled with EdU (1 μM) and incubated for a further 24 h. At that point, cells were labeled with anti-IgM and anti-IgD mAbs and the percentage of IgM⁺IgD⁺ B cells with incorporated EdU (proliferating cells) determined as described in the Materials and Methods section. Representative dot plots are presented along with a graph showing the quantification of proliferating IgM⁺IgD⁺ B cells (mean + SEM; n = 8).